Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284758 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
A Phase 2 study of Multiple Myeloma and Relapsed/Refractory Multiple Myeloma, sponsored by C4 Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 3
- Study locations
NCT07284758: Recruiting Phase 2 study of Multiple Myeloma and Relapsed/Refractory Multiple Myeloma, sponsored by C4 Therapeutics.
NCT07284758 is a Phase 2 study of Multiple Myeloma and Relapsed/Refractory Multiple Myeloma that is actively recruiting participants, run by C4 Therapeutics. The registered enrollment target is 100 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07284758, a Phase 2 study of Multiple Myeloma and Relapsed/Refractory Multiple Myeloma, is actively recruiting participants, sponsored by C4 Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Cemsidomide
Study Locations (3)
California
- Berenson Cancer Center - West Hollywood
Michigan
- START Midwest - Grand Rapids
Texas
- START San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2030-03 |
| Phase | Phase 2 |
What NCT07284758 shows while recruiting
NCT07284758 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT07284758 reports a single indexed study location in California, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT07284758 about?
NCT07284758 is a clinical study titled "A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma". This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
What is the current status of trial NCT07284758?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-02-18. Estimated completion is 2030-03.
What conditions does trial NCT07284758 study?
This clinical trial studies the following conditions: Multiple Myeloma, Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT07284758?
The interventions under investigation include: Dexamethasone (DRUG), Cemsidomide (DRUG).
Who is sponsoring clinical trial NCT07284758?
This trial is sponsored by C4 Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284758 being conducted?
This trial has 3 study locations across California, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07284758's enrollment target sits among peer trials
100 165th of 438 higher than 262 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI